BRPI0906903A2 - ''anticorpo kit de diagnóstico, método de detecção da expressão de cd70 em uma amostra de tecido, método para prognosticar, determinar um protocolo de tratamento ou monitorar o tratamento, uso de um agente de ligação a cd70 e combinação de um kit de diagnóstico e um kit farmacêutico - Google Patents
''anticorpo kit de diagnóstico, método de detecção da expressão de cd70 em uma amostra de tecido, método para prognosticar, determinar um protocolo de tratamento ou monitorar o tratamento, uso de um agente de ligação a cd70 e combinação de um kit de diagnóstico e um kit farmacêuticoInfo
- Publication number
- BRPI0906903A2 BRPI0906903A2 BRPI0906903A BRPI0906903A BRPI0906903A2 BR PI0906903 A2 BRPI0906903 A2 BR PI0906903A2 BR PI0906903 A BRPI0906903 A BR PI0906903A BR PI0906903 A BRPI0906903 A BR PI0906903A BR PI0906903 A2 BRPI0906903 A2 BR PI0906903A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnostic kit
- kit
- treatment
- predicting
- expression
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4445708P | 2008-04-11 | 2008-04-11 | |
| US61/044,457 | 2008-04-11 | ||
| PCT/US2009/040275 WO2009126934A2 (en) | 2008-04-11 | 2009-04-10 | Detection and tratment of pancreatic, ovarian and other cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0906903A2 true BRPI0906903A2 (pt) | 2015-12-01 |
| BRPI0906903B1 BRPI0906903B1 (pt) | 2020-07-07 |
| BRPI0906903B8 BRPI0906903B8 (pt) | 2021-05-25 |
Family
ID=41162668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906903A BRPI0906903B8 (pt) | 2008-04-11 | 2009-04-10 | anticorpo monoclonal e método de detecção da expressão de cd70 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9120854B2 (pt) |
| EP (1) | EP2276509B1 (pt) |
| JP (2) | JP5752592B2 (pt) |
| KR (1) | KR101674097B1 (pt) |
| CN (1) | CN102056626B (pt) |
| AU (1) | AU2009234267B2 (pt) |
| BR (1) | BRPI0906903B8 (pt) |
| CA (1) | CA2720699C (pt) |
| DK (1) | DK2276509T3 (pt) |
| ES (1) | ES2588194T3 (pt) |
| IL (1) | IL208517A (pt) |
| MY (1) | MY159553A (pt) |
| NZ (1) | NZ589063A (pt) |
| RU (1) | RU2556129C2 (pt) |
| SG (1) | SG189776A1 (pt) |
| WO (1) | WO2009126934A2 (pt) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58103228A (ja) * | 1981-12-16 | 1983-06-20 | Kaga Tsushin Kogyo Kk | 光スイツチ方法 |
| GB0522968D0 (en) | 2005-11-11 | 2005-12-21 | Popovich Milan M | Holographic illumination device |
| GB0718706D0 (en) | 2007-09-25 | 2007-11-07 | Creative Physics Ltd | Method and apparatus for reducing laser speckle |
| US11726332B2 (en) | 2009-04-27 | 2023-08-15 | Digilens Inc. | Diffractive projection apparatus |
| US9335604B2 (en) | 2013-12-11 | 2016-05-10 | Milan Momcilo Popovich | Holographic waveguide display |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| EP2686347B1 (en) * | 2011-03-16 | 2018-05-02 | argenx BVBA | Antibodies to cd70 |
| CN102719403B (zh) * | 2011-03-29 | 2016-01-20 | 上海睿智化学研究有限公司 | 一种人胰腺腺鳞癌细胞系及其建立方法和应用 |
| US9274349B2 (en) | 2011-04-07 | 2016-03-01 | Digilens Inc. | Laser despeckler based on angular diversity |
| EP2748670B1 (en) | 2011-08-24 | 2015-11-18 | Rockwell Collins, Inc. | Wearable data display |
| US10670876B2 (en) | 2011-08-24 | 2020-06-02 | Digilens Inc. | Waveguide laser illuminator incorporating a despeckler |
| WO2016020630A2 (en) | 2014-08-08 | 2016-02-11 | Milan Momcilo Popovich | Waveguide laser illuminator incorporating a despeckler |
| MX353958B (es) * | 2011-09-22 | 2018-02-07 | Amgen Inc | Proteinas de union al antigeno cd27l. |
| US20150010265A1 (en) | 2012-01-06 | 2015-01-08 | Milan, Momcilo POPOVICH | Contact image sensor using switchable bragg gratings |
| WO2013120082A1 (en) * | 2012-02-10 | 2013-08-15 | Kassab Ghassan S | Methods and uses of biological tissues for various stent and other medical applications |
| EP2842003B1 (en) | 2012-04-25 | 2019-02-27 | Rockwell Collins, Inc. | Holographic wide angle display |
| US9456744B2 (en) | 2012-05-11 | 2016-10-04 | Digilens, Inc. | Apparatus for eye tracking |
| US9933684B2 (en) | 2012-11-16 | 2018-04-03 | Rockwell Collins, Inc. | Transparent waveguide display providing upper and lower fields of view having a specific light output aperture configuration |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| WO2014158821A1 (en) * | 2013-03-12 | 2014-10-02 | Imaginab, Inc. | Antigen binding constructs to cd70 |
| JP6847388B2 (ja) * | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| US10209517B2 (en) | 2013-05-20 | 2019-02-19 | Digilens, Inc. | Holographic waveguide eye tracker |
| US9727772B2 (en) | 2013-07-31 | 2017-08-08 | Digilens, Inc. | Method and apparatus for contact image sensing |
| HRP20190888T8 (hr) | 2014-04-25 | 2019-10-04 | Pierre Fabre Médicament | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma |
| HUE047952T2 (hu) | 2014-04-25 | 2020-05-28 | Pf Medicament | Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra |
| WO2015183978A1 (en) | 2014-05-28 | 2015-12-03 | Agensys, Inc. | Derivatives of dolaproine-dolaisoleuine peptides |
| DE102014108642B3 (de) * | 2014-06-19 | 2015-12-03 | Laser Zentrum Hannover E.V. | Einbettmedium für biologische Proben und Verfahren zum Herstellen von eingebetteten biologischen Proben sowie deren Verwendung |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| WO2016020632A1 (en) | 2014-08-08 | 2016-02-11 | Milan Momcilo Popovich | Method for holographic mastering and replication |
| WO2016042283A1 (en) | 2014-09-19 | 2016-03-24 | Milan Momcilo Popovich | Method and apparatus for generating input images for holographic waveguide displays |
| EP3198192A1 (en) | 2014-09-26 | 2017-08-02 | Milan Momcilo Popovich | Holographic waveguide opticaltracker |
| US10437064B2 (en) | 2015-01-12 | 2019-10-08 | Digilens Inc. | Environmentally isolated waveguide display |
| EP3245551B1 (en) | 2015-01-12 | 2019-09-18 | DigiLens Inc. | Waveguide light field displays |
| CN107533137A (zh) | 2015-01-20 | 2018-01-02 | 迪吉伦斯公司 | 全息波导激光雷达 |
| US9632226B2 (en) | 2015-02-12 | 2017-04-25 | Digilens Inc. | Waveguide grating device |
| WO2016146963A1 (en) | 2015-03-16 | 2016-09-22 | Popovich, Milan, Momcilo | Waveguide device incorporating a light pipe |
| US10591756B2 (en) | 2015-03-31 | 2020-03-17 | Digilens Inc. | Method and apparatus for contact image sensing |
| WO2017060665A1 (en) | 2015-10-05 | 2017-04-13 | Milan Momcilo Popovich | Waveguide display |
| EP3398007B1 (en) | 2016-02-04 | 2024-09-11 | DigiLens, Inc. | Waveguide optical tracker |
| JP6895451B2 (ja) | 2016-03-24 | 2021-06-30 | ディジレンズ インコーポレイテッド | 偏光選択ホログラフィー導波管デバイスを提供するための方法および装置 |
| EP3433658B1 (en) | 2016-04-11 | 2023-08-09 | DigiLens, Inc. | Holographic waveguide apparatus for structured light projection |
| EP3548939A4 (en) | 2016-12-02 | 2020-11-25 | DigiLens Inc. | UNIFORM OUTPUT LIGHTING WAVEGUIDE DEVICE |
| US10545346B2 (en) | 2017-01-05 | 2020-01-28 | Digilens Inc. | Wearable heads up displays |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN111386495B (zh) | 2017-10-16 | 2022-12-09 | 迪吉伦斯公司 | 用于倍增像素化显示器的图像分辨率的系统和方法 |
| JP7404243B2 (ja) | 2018-01-08 | 2023-12-25 | ディジレンズ インコーポレイテッド | 導波管セル内のホログラフィック格子の高スループット記録のためのシステムおよび方法 |
| JP7456929B2 (ja) | 2018-01-08 | 2024-03-27 | ディジレンズ インコーポレイテッド | 導波管セルを製造するためのシステムおよび方法 |
| WO2019136476A1 (en) | 2018-01-08 | 2019-07-11 | Digilens, Inc. | Waveguide architectures and related methods of manufacturing |
| CN114721242B (zh) | 2018-01-08 | 2025-08-15 | 迪吉伦斯公司 | 用于制造光学波导的方法 |
| US20230158070A1 (en) | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| US10690851B2 (en) | 2018-03-16 | 2020-06-23 | Digilens Inc. | Holographic waveguides incorporating birefringence control and methods for their fabrication |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| US11402801B2 (en) | 2018-07-25 | 2022-08-02 | Digilens Inc. | Systems and methods for fabricating a multilayer optical structure |
| WO2020149956A1 (en) | 2019-01-14 | 2020-07-23 | Digilens Inc. | Holographic waveguide display with light control layer |
| US20200247017A1 (en) | 2019-02-05 | 2020-08-06 | Digilens Inc. | Methods for Compensating for Optical Surface Nonuniformity |
| EP3924759B1 (en) | 2019-02-15 | 2025-07-30 | Digilens Inc. | Methods and apparatuses for providing a holographic waveguide display using integrated gratings |
| US20220283377A1 (en) | 2019-02-15 | 2022-09-08 | Digilens Inc. | Wide Angle Waveguide Display |
| JP2022525165A (ja) | 2019-03-12 | 2022-05-11 | ディジレンズ インコーポレイテッド | ホログラフィック導波管バックライトおよび関連する製造方法 |
| CN113795264A (zh) | 2019-03-19 | 2021-12-14 | 瓦尔希伯伦私人肿瘤研究基金会 | 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法 |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| EP3980825A4 (en) | 2019-06-07 | 2023-05-03 | Digilens Inc. | WAVEGUIDES WITH TRANSMITTING AND REFLECTING GRIDS AND RELATED MANUFACTURING PROCESSES |
| JP2022543571A (ja) | 2019-07-29 | 2022-10-13 | ディジレンズ インコーポレイテッド | 画素化されたディスプレイの画像解像度および視野を乗算するための方法および装置 |
| JP2022546413A (ja) | 2019-08-29 | 2022-11-04 | ディジレンズ インコーポレイテッド | 真空回折格子および製造方法 |
| US20210380707A1 (en) * | 2020-06-04 | 2021-12-09 | Crispr Therapeutics Ag | Anti-cd70 antibodies and uses thereof |
| EP4252048A4 (en) | 2020-12-21 | 2024-10-16 | Digilens Inc. | EYE LUMINESCENCE SUPPRESSION IN WAVEGUIDE-BASED DISPLAYS |
| WO2022150841A1 (en) | 2021-01-07 | 2022-07-14 | Digilens Inc. | Grating structures for color waveguides |
| RU2750472C1 (ru) * | 2021-01-26 | 2021-06-28 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Малоинвазивный способ диагностики серозной аденокарциномы яичников высокой степени злокачественности на основании показателя копийности генов SULT1E1, CYP1B1 и ESR1 |
| KR20230153459A (ko) | 2021-03-05 | 2023-11-06 | 디지렌즈 인코포레이티드. | 진공 주기적 구조체 및 제조 방법 |
| CN113754769B (zh) * | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd70的抗体及其制备和用途 |
| EP4608429A1 (en) | 2022-10-25 | 2025-09-03 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
| IL324909A (en) | 2023-06-07 | 2026-01-01 | Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron | Combination therapy with mek inhibitors for the treatment of cancer |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| IL325025A (en) | 2023-06-07 | 2026-01-01 | Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron | Combination therapy with BRAF inhibitors for cancer treatment |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| AU2227999A (en) * | 1998-01-14 | 1999-08-02 | Human Genome Sciences, Inc. | Human ependymin |
| CA2411601A1 (en) | 2000-06-05 | 2001-12-13 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| ES2394018T3 (es) | 2001-11-27 | 2013-01-15 | Ucb Pharma S.A. | Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| WO2005077462A2 (en) | 2004-02-09 | 2005-08-25 | The Cbr Institute For Biomedical Research, Inc. | Cd70 inhibition for the treatment and prevention of inflammatory bowel disease |
| KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| WO2005118788A2 (en) * | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| WO2006044643A2 (en) | 2004-10-15 | 2006-04-27 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| CN101370830A (zh) * | 2005-09-26 | 2009-02-18 | 米德列斯公司 | 抗cd70的人单克隆抗体 |
| NZ566395A (en) * | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| MX2009006277A (es) | 2006-12-14 | 2009-07-24 | Medarex Inc | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. |
-
2009
- 2009-04-10 US US12/937,190 patent/US9120854B2/en active Active
- 2009-04-10 MY MYPI2010004696A patent/MY159553A/en unknown
- 2009-04-10 RU RU2010145942/10A patent/RU2556129C2/ru active
- 2009-04-10 EP EP09729923.4A patent/EP2276509B1/en active Active
- 2009-04-10 BR BRPI0906903A patent/BRPI0906903B8/pt not_active IP Right Cessation
- 2009-04-10 CN CN200980121463.0A patent/CN102056626B/zh not_active Expired - Fee Related
- 2009-04-10 SG SG2013027248A patent/SG189776A1/en unknown
- 2009-04-10 WO PCT/US2009/040275 patent/WO2009126934A2/en not_active Ceased
- 2009-04-10 JP JP2011504225A patent/JP5752592B2/ja not_active Expired - Fee Related
- 2009-04-10 AU AU2009234267A patent/AU2009234267B2/en not_active Ceased
- 2009-04-10 CA CA2720699A patent/CA2720699C/en active Active
- 2009-04-10 KR KR1020107024974A patent/KR101674097B1/ko not_active Expired - Fee Related
- 2009-04-10 DK DK09729923.4T patent/DK2276509T3/en active
- 2009-04-10 NZ NZ589063A patent/NZ589063A/xx not_active IP Right Cessation
- 2009-04-10 ES ES09729923.4T patent/ES2588194T3/es active Active
-
2010
- 2010-10-06 IL IL208517A patent/IL208517A/en active IP Right Grant
-
2014
- 2014-06-18 JP JP2014125002A patent/JP2014218502A/ja active Pending
-
2015
- 2015-07-13 US US14/798,379 patent/US20160003847A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014218502A (ja) | 2014-11-20 |
| JP2011520782A (ja) | 2011-07-21 |
| AU2009234267A1 (en) | 2009-10-15 |
| AU2009234267B2 (en) | 2014-10-30 |
| ES2588194T3 (es) | 2016-10-31 |
| WO2009126934A3 (en) | 2009-12-30 |
| CA2720699C (en) | 2018-01-02 |
| NZ589063A (en) | 2012-10-26 |
| US9120854B2 (en) | 2015-09-01 |
| KR20110010719A (ko) | 2011-02-07 |
| CA2720699A1 (en) | 2009-10-15 |
| US20110300131A1 (en) | 2011-12-08 |
| EP2276509A4 (en) | 2013-03-13 |
| IL208517A (en) | 2016-06-30 |
| EP2276509B1 (en) | 2016-06-15 |
| MY159553A (en) | 2017-01-13 |
| KR101674097B1 (ko) | 2016-11-08 |
| CN102056626B (zh) | 2016-07-06 |
| EP2276509A2 (en) | 2011-01-26 |
| RU2556129C2 (ru) | 2015-07-10 |
| BRPI0906903B8 (pt) | 2021-05-25 |
| JP5752592B2 (ja) | 2015-07-22 |
| US20160003847A1 (en) | 2016-01-07 |
| RU2010145942A (ru) | 2012-05-20 |
| IL208517A0 (en) | 2010-12-30 |
| SG189776A1 (en) | 2013-05-31 |
| WO2009126934A2 (en) | 2009-10-15 |
| BRPI0906903B1 (pt) | 2020-07-07 |
| DK2276509T3 (en) | 2016-09-19 |
| CN102056626A (zh) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0906903A2 (pt) | ''anticorpo kit de diagnóstico, método de detecção da expressão de cd70 em uma amostra de tecido, método para prognosticar, determinar um protocolo de tratamento ou monitorar o tratamento, uso de um agente de ligação a cd70 e combinação de um kit de diagnóstico e um kit farmacêutico | |
| BRPI0906261A2 (pt) | "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente" | |
| BRPI0717697A2 (pt) | composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos | |
| BRPI0909620A2 (pt) | "dispositivo microfluídico para detectar a presença de um ou mais análitos em uma amostra de saliva, método para detectar a presença de um ou mais análitos em uma amostra de saliva e método para detectar em um dispositivo microfluídico um análito e uma amostra de saliva que copreende a mucina" | |
| BR112013006764A2 (pt) | método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente | |
| BRPI0807927A2 (pt) | Métodos para determinar uma susceptibilidade a doença cardiovascular em um indivíduo humano, de identificação de um marcador para uso para avaliar susceptibilidade a doença cardiovascular, para genotipar uma amostra de ácido nucleico, para avaliar um indivíduo para probabilidade de resposta a um agente terapêutico, para predizer prognóstico de um indivíduo diagnosticado com doença cardiovascular, e para monitorar progresso de tratamento de um indivíduo passando por tratamento para doença cardiovascular, kit para avaliar susceptibilidade a doença cardiovascular em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para doença cardiovascular em um indivíduo humano | |
| BRPI0820568A2 (pt) | Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal | |
| BRPI0920261A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica | |
| WO2012031008A3 (en) | Cancer-related biological materials in microvesicles | |
| BRPI1006733A2 (pt) | kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método | |
| WO2009132058A3 (en) | Levels of bcma protein expression on b cells and use in diagnostic methods | |
| BRPI0918194A2 (pt) | ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
| BRPI0916235A2 (pt) | composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv | |
| WO2008021290A3 (en) | Organ-specific proteins and methods of their use | |
| IT1406051B1 (it) | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. | |
| BRPI0812575A2 (pt) | Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos | |
| BRPI0717219A2 (pt) | "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica." | |
| BRPI0909791A2 (pt) | Cartucho, dispositivo sensor e método para detecção de componentes alvo em uma amostra líquida, e, uso do cartucho ou do dispositivo sensor. | |
| BR112012024841A2 (pt) | ''composição de diagnóstico para utilização na análise de um líquido viscoelástico de teste, recipiente, método de realizar uma análise viscoelástica em líquido de teste e uso de uma composição de diagnóstico'' | |
| BRPI1015088A2 (pt) | peptídeo antigênio ou um fragmento funcional deste, composição farmacêutica, métodos para o tratamento de uma doença ou distúrbio neurodegenerativos tal como tauopatia, para induzir uma resposta imune em um animal, para diagnosticar uma doença, distúrbio ou condição e uma predisposição a doença, distúrbio ou condição, para monitorar a doença residual mínima em um paciente e para prever a receptividade de um paciente, anticorpo, kit de teste, epítopo e linha celular. | |
| BRPI0915619A2 (pt) | métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra | |
| BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
| BRPI0814339A2 (pt) | composição farmacêutica, kit para a preparação da composição farmacêutica, conjugado, e, métodos de formação de imagem óptica in vivo do corpo de mamíferos, e de detecção, estabilização, diagnóstico, monitoramento do progresso da doença ou monitoramento do tratamento de um estado doentio do corpon dos mamíferos | |
| BRPI0918211A2 (pt) | métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf | |
| BRPI0916101A2 (pt) | "método para determinar o estágio de uma gravidez, dispositivo adaptado para detectar os níveis/a quantidade de hpl ou de um fragmento do mesmo em uma amostra de fluido corpóreo derivado de uma fêmea humana, kit e uso de um anticorpo anti-hpl" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/07/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25D | Requested change of name of applicant approved |
Owner name: SEAGEN INC. (US) |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |